NCT07464925

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-04-20Est. Completion: 2027-06

Enrollment target: 30 participants

Locations

Moffitt Cancer Center, Tampa, Florida, United States
Northwestern Medicine, Chicago, Illinois, United States
NYU Langone Health, New York, New York, United States

Other microbiome trials you might be interested in

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPhase 1Recruiting

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed CancerRecurrent TumorGlioblastoma MultiformeRecurring GlioblastomaBrain and Central Nervous System TumorsGliomaGlioblastomasGrade IV AstrocytomaGBMRecurrent Glioma (Glioblastoma Multiforme)High Grade GliomaGlioma, MalignantBrain Cancer

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…

Bethesda, United StatesEst. completion Dec 31, 2030

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.